Article

Daily Medication Pearl: Hyqvia Immune Globulin Infusion 10%

Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency in adults.

Medication Pearl of the Day: Hyqvia Immune Globulin Infusion 10%

Indication: Hyqvia is an immune globulin with a recombinant human hyaluronidase indicated for the treatment of primary immunodeficiency (PI) in adults.

Insight:

  • Dosing: May start from 7.5 g up to 30 g infusions depending on the patient.
  • Dosage forms: Comes in 10%, 2.5, 5-, 10-, 20-, and 30-gram proteins.
  • Adverse events: The most common adverse reactions observed in clinical trials in >5% of subjects were local reactions, headache, antibody formation against recombinant human hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.
  • Mechanism of action: The immune globulin infusion 10% (human) provides the therapeutic effect of Hyqvia. The recombinant human hyaluronidase of Hyqvia increases dispersion and absorption of the immune globulin infusion 10% (human). The immune globulin infusion 10% (human) of Hyqvia supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.

Source: HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant (fda.gov)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
© 2025 MJH Life Sciences

All rights reserved.